SCHEMBL4260331

SCHEMBL4260331

Cc1cc(N2CCOCC2)cc(C)c1CC(N)=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 10/20 0.46
GAA P10253 1/20 0.46
LMNA P02545 2/20 0.46
KDM4E B2RXH2 4/20 0.44
ALDH1A1 P00352 3/20 0.42
ALOX15 P16050 2/20 0.42
MEN1 O00255 2/20 0.42
USP2 O75604 2/20 0.42
HTT P42858 2/20 0.42
KMT2A Q03164 2/20 0.42
TP53 P04637 1/20 0.42
MAPK1 P28482 1/20 0.42
HSD17B10 Q99714 1/20 0.42
PRKDC P78527 1/20 0.41
GSK3B P49841 1/20 0.41
L3MBTL1 Q9Y468 3/20 0.40
AKR1C3 P42330 1/20 0.40
KMO O15229 1/20 0.40
PLAU P00749 1/20 0.39
POLB P06746 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4259602 0.89 MAPT (0.48) MAPTGAALMNAKDM4EALDH1A1
SCHEMBL2770127 0.80 MAPT (0.49) MAPTGAALMNAKDM4EALDH1A1
SCHEMBL3242500 0.79 IKBKB (0.50) GAAKDM4EALDH1A1ALOX15MEN1
SCHEMBL20338990 0.79 KDM4E (0.53) MAPTGAALMNAKDM4EALDH1A1
SCHEMBL27883229 0.76 MAPT (0.46) MAPTGAALMNAKDM4EALDH1A1
SCHEMBL15752632 0.74 SMN1; SMN2 (0.55) MAPTGAALMNAALDH1A1MEN1
SCHEMBL2436520 0.73 KDM4E (0.55) MAPTGAALMNAKDM4EALDH1A1
SCHEMBL3230406 0.73 PRKDC (0.58) MAPTGAALMNAKDM4EALDH1A1
SCHEMBL14672518 0.73 KDM4E (0.54) MAPTGAAKDM4EALDH1A1MEN1
SCHEMBL14379370 0.73 KDM4E (0.58) MAPTGAALMNAKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090118285-A1 USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA H. LUNDBECK A/S (DK) 2009-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090118285-A1 USE OF KCNQ-OPENERS FOR TREATING OR REDUCING THE SYMPTOMS OF SCHIZOPHRENIA KCNQ4, KCNQ5, KCNQ1 MAPT 1786/4885GAA 2182/4885LMNA 3032/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.